Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 5Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gynecologic 5Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Breast Neoplasms 6Neoplasms 5Carcinoma, Ovarian Epithelial 5Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Small Cell Lung Carcinoma 2Metastatic Castration Resistant Prostate Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Lung Neoplasms 1Genital Neoplasms, Male 1Genital Neoplasms, Female 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Gastric Cancer 1Adenocarcinoma, Clear Cell 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 69Paclitaxel 63Cisplatin 32Topotecan 29Gemcitabine 21Docetaxel 20Cyclophosphamide 18Filgrastim 17liposomal doxorubicin 15Peripheral Blood Stem Cell Transplantation 15Bevacizumab 14sargramostim 11Taxes 10Drug Therapy 10Therapeutics 7Psychiatric Rehabilitation 7Immunohistochemistry 7Erlotinib Hydrochloride 7Amifostine 7Melphalan 6Chemotherapy, Adjuvant 6rucaparib 5pembrolizumab 5mirvetuximab soravtansine 5ixabepilone 5Surgical Procedures, Operative 5Mass Spectrometry 5Interleukin-12 Subunit p35 5Flow Cytometry 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ovarian Epithelial × rucaparib × Clear all
NCT04539327 2026-03-18

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

Grupo Español de Investigación en Cáncer de Ovario

Completed
51 enrolled 28 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04676334 2024-05-07

CATCH-R

pharmaand GmbH

Phase 3 Completed
34 enrolled 9 charts
GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Male, Ovarian Neoplasms, Prostatic Neoplasms

NCT01891344 2023-06-12

ARIEL2

pharmaand GmbH

Phase 2 Completed
491 enrolled 19 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

pharmaand GmbH

Phase 3 Completed
349 enrolled 29 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT00664781 2016-05-24

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Cancer Research UK

Phase 2 Completed
78 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡